仁和藥業(000650.SZ)子公司銅鼓仁和獲高新技術企業認定
格隆匯1月21日丨仁和藥業(000650.SZ)公佈,近日,公司下屬子公司江西銅鼓仁和製藥有限公司(“銅鼓仁和”)收到江西省科學技術廳、江西省財政廳、國家税務總局江西省税務局聯合下發的《高新技術企業證書》(證書編號GR201936000552),銅鼓仁和被認定為江西省高新技術企業,
此次高新技術企業資格有效期為三年(自2019年9月16日至2022年9月15日)。根據國家對高新技術企業的相關税收優惠政策,銅鼓仁和自獲得高新技術企業認定後三年內可享受國家關於高新技術企業的相關優惠政策,按15%的税率繳納企業所得税。
目前,公司下屬江西藥都仁和製藥有限公司、江西閃亮製藥有限公司、江西藥都樟樹製藥有限公司、江西製藥有限責任公司、江西銅鼓仁和製藥有限公司、江西康美醫藥保健品有限公司等多家子公司被認定為“高新技術企業”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.